Claims
- 1. A solution for intravenous administration containing water, lubeluzole or a pharmaceutically acceptable addition salt thereof, an isotonizing agent, and acid and base substances to adjust the pH of the solution in the range from 2.5 to 3.6.
- 2. A solution according to claim 1 wherein the isotonizing agent is glucose.
- 3. A solution according to claim 1 comprising acid and base substances to adjust the pH of the solution in the range from 3.0 to 3.4.
- 4. A solution according to claim 1 comprising:
- (a) 0.005 to 5% lubeluzole or a pharmaceutically acceptable addition salt thereof;
- (b) 1 to 10% isotonizing agent;
- (c) acid and/or base substances to adjust the pH in the range from 2.5 to 3.6; and
- (d) water q.s. ad 100%.
- 5. A solution according to claim 4 comprising:
- (a) 0.01 to 1% lubeluzole or a pharmaceutically acceptable addition salt thereof;
- (b) 2 to 10% glucose;
- (c) hydrochloric acid and sodium hydroxide to adjust the pH in the range from 3.0 to 3.4; and
- (d) water q.s. ad 100%.
- 6. A solution according to claim 5 containing approximately:
- (a) 0.05% lubeluzole or a pharmaceutically acceptable addition salt thereof;
- (b) 5% glucose;
- (c) hydrochloric acid and sodium hydroxide to adjust the pH to about 3.2; and
- (d) water q.s. ad 100%.
- 7. A solution according to claim 1 wherein the isotonizing agent is sodium chloride.
- 8. A solution according to claim 1 comprising:
- (a) 0.005 to 5% lubeluzole or a pharmaceutically acceptable addition salt thereof;
- (b) 0.1 to 2% isotonizing agent;
- (c) acid and/or base substances to adjust the pH in the range from 2.5 to 3.6; and
- (d) water q.s. ad 100%.
- 9. A solution according to claim 8 comprising:
- (a) 0.005 to 0.1% lubeluzole or a pharmaceutically acceptable addition salt thereof;
- (b) 0.4 to 1.8% sodium chloride;
- (c) hydrochloric acid and sodium hydroxide to adjust the pH in the range from 3.0 to 3.4; and
- (d) water q.s. ad 100%.
- 10. A solution according to claim 9 containing approximately:
- (a) 0.02% lubeluzole or a pharmaceutically acceptable addition salt thereof;
- (b) 0.9% sodium chloride;
- (c) hydrochloric acid and sodium hydroxide to adjust the pH to about 3.2; and
- (d) water q.s. ad 100%.
- 11. A pre-filled syringe comprising a solution according to any one of claims 1 to 10.
- 12. A pre-filled syringe according to claim 11 adapted for use with infusor devices.
- 13. An infusion pack for the acute treatment of stroke comprising a solution according to any one of claims 1 to 10, and a disposable, independent drive unit.
- 14. An infusion pack according to claim 13 wherein the independent drive unit is gas-operated or vaccuum-operated.
- 15. An infusion pack for the acute treatment of stroke comprising a solution according to any of claims 1 to 10, and a disposable, independent drive unit, wherein the solution is contained in a pre-filled syringe adapted for use with infusor devices.
Priority Claims (1)
Number |
Date |
Country |
Kind |
94203422 |
Nov 1994 |
EPX |
|
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is the national stage of application No. PCT/EP 95/04520, filed on Nov. 16, 1995, which application claims priority from EP 94.203.422.4, filed on Nov. 24, 1994.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
102e Date |
371c Date |
PCT/EP95/04520 |
11/16/1995 |
|
|
4/23/1997 |
4/23/1997 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO96/15790 |
5/30/1996 |
|
|
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
5010198 |
Stokbroekx et al. |
Apr 1991 |
|
5434168 |
Stokbroekx et al. |
Jul 1995 |
|